{"nctId":"NCT00496730","briefTitle":"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin速 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)","startDateStruct":{"date":"2007-07"},"conditions":["Hypercholesterolemia"],"count":256,"armGroups":[{"label":"Vytorin速","type":"EXPERIMENTAL","interventionNames":["Drug: simvastatin (+) ezetimibe"]},{"label":"atorvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: atorvastatin"]}],"interventions":[{"name":"simvastatin (+) ezetimibe","otherNames":["MK0653A","Vytorin速"]},{"name":"Comparator: atorvastatin","otherNames":["Lipitor速"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of the metabolic syndrome according to 2005 American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) scientific statement\n* No history of diabetes and 100 \\<=LDL-C \\<=250 mg/dl\n\nExclusion Criteria:\n\n* Myocardial Infarction, coronary artery bypass surgery, or angioplasty within 3 months\n* Congestive heart failure defined by New York Heart Association (NYHA) class III or IV\n* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins\n* Uncontrolled hypertension\n* Unstable angina","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.29","spread":"15.22"},{"groupId":"OG001","value":"-38.05","spread":"12.28"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.","description":"Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.\n\nLDL-C goal is based on National Cholesterol Education Program (NCEP) III guideline (LDL-C goals and cutpoints for therapeutic life changes and drug Therapy in different risk).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.52","spread":"33.84"},{"groupId":"OG001","value":"98.27","spread":"21.82"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Hypercholesterolaemia","High Density lipoprotein decreased","Hypertriglyceridaemia","Hepatic enzyme increased","Abdominal pain upper"]}}}